高级搜索
潘剑茹, 韩亚南, 何夏琪, 叶小强, 何火聪. 带前导肽的人锰超氧化物歧化酶抗顺铂诱导的肾损伤效应[J]. 肿瘤防治研究, 2023, 50(7): 675-680. DOI: 10.3971/j.issn.1000-8578.2023.22.1465
引用本文: 潘剑茹, 韩亚南, 何夏琪, 叶小强, 何火聪. 带前导肽的人锰超氧化物歧化酶抗顺铂诱导的肾损伤效应[J]. 肿瘤防治研究, 2023, 50(7): 675-680. DOI: 10.3971/j.issn.1000-8578.2023.22.1465
PAN Jianru, HAN Ya'nan, HE Xiaqi, YE Xiaoqiang, HE Huocong. Anti-cisplatin-induced Renal-injury Effect of Human Manganese Superoxide Dismutase with Leader Peptide[J]. Cancer Research on Prevention and Treatment, 2023, 50(7): 675-680. DOI: 10.3971/j.issn.1000-8578.2023.22.1465
Citation: PAN Jianru, HAN Ya'nan, HE Xiaqi, YE Xiaoqiang, HE Huocong. Anti-cisplatin-induced Renal-injury Effect of Human Manganese Superoxide Dismutase with Leader Peptide[J]. Cancer Research on Prevention and Treatment, 2023, 50(7): 675-680. DOI: 10.3971/j.issn.1000-8578.2023.22.1465

带前导肽的人锰超氧化物歧化酶抗顺铂诱导的肾损伤效应

Anti-cisplatin-induced Renal-injury Effect of Human Manganese Superoxide Dismutase with Leader Peptide

  • 摘要:
    目的 探讨前导肽的融合对人锰超氧化物歧化酶(SOD2)结构以及抗顺铂(DDP)诱导的肾损伤效应。
    方法 通过结构预测和SOD比活力测定分析线粒体靶向序列(MTS)对SOD2构效的影响;建立昆明(KM)小鼠DDP损伤模型,以阿米福汀(AMFT)为阳性对照,测定小鼠肾功能、肾脏指数、肾脏抗氧化能力,同时观察肾脏表观及病理变化,以评估MTS-SOD2抗DDP诱导的肾损伤效应。
    结果 MTS前导肽对SOD2的二三级结构有一定影响,但也使MTS-SOD2蛋白的比活力提高。预给予中剂量MTS-SOD2(0.84 mg/kg)可以使损伤鼠肾脏丙二醛(MDA)水平显著降低,SOD活力和总抗氧化能力(T-AOC)显著增加,进而减少肾脏病理损伤,维持肾功能,整体效果与200 mg/kg AMFT相当甚至优于后者。
    结论 MTS前导肽既增强了SOD2的活性,又使其因具有跨膜功能而发挥优异的抗DDP诱导的肾损伤效应。

     

    Abstract:
    Objective To investigate the effect of the fusion of leader peptide on the structure of human manganese superoxide dismutase (SOD2) and anti-cisplatin (DDP)-induced renal injury.
    Methods The effect of mitochondrion targeting sequence (MTS) on the structure and activity of SOD2 was analyzed by structure prediction and superoxide dismutase (SOD) specific-activity determination. The DDP injury model of Kunming (KM) mice was established, and amifostine (AMFT) was set as a positive control. Indicators such as kidney index, renal function, kidney antioxidant capacity, and appearance and pathology changes of mice kidney were used to evaluate the effect of MTS-SOD2 against DDP-induced kidney injury.
    Results The MTS leader peptide seemed to change the secondary and tertiary structures of SOD2 to some extent, but it also increased the specific activity of the MTS-SOD2 protein. Pre-administration of a medium dose of MTS-SOD2 (0.84 mg/kg) before the use of DDP significantly reduced the level of renal malondialdehyde and increased the SOD activity and total antioxidant capacity (T-AOC) in the kidney, thereby reducing the renal pathological damage and consequently maintaining renal function. The overall protective effect of MTS-SOD2 was comparable to or even better than that of 200 mg/kg AMFT.
    Conclusion The MTS leader peptide enhances the activity of SOD2 and confers it with an excellent anti-DDP-induced renal-injury effect because of its transmembrane function.

     

/

返回文章
返回